Copy into your RSS Reader
Copy into your Podcast App
A Novartis office in Mumbai, India.
Divyakant Solanki /EPA /LANDOV
April 1, 2013 Novartis lost its bid to patent one of its cancer drugs. Indian authorities say the drug is too much like an earlier version. Novartis says the ruling may dampen drug companies' willingness to work in India. Others say the ruling will help make less expensive drugs available to the world's poor.
<iframe src="http://www.npr.org/player/embed/175916808/175955763" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
NPR thanks our sponsors
Become an NPR sponsor